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Summary 
Inoculated immunogenic cancer cells after initial growth are potentially rejected by specific host 
immunity; however, the outcome of the interaction between host and inoculated cancer cells 
is a function of multiple factors including the route of inoculation, the number of cells,  the 
density of antigens on the injected cancer cells, and the state of the immune system of the host. 
In the present study, we have examined a different kind of variable:  the stroma that inoculated 
tumor cells initially reside in. The impetus to examine this factor arises from observations that 
cancer cells from several lines inoculated as fragments of solid tumors often grow progressively, 
whereas the same number or more than 10-fold larger numbers of identical type cells injected 
as a suspension are rejected, even though fragments or suspended cells are both tumorigenic 
at the same doses in nude mice. In the present studies, we found that: (a) indeed, cancer cells 
inoculated  as  fragments  were  more  tumorigenic  than  cancer  cells  in  suspension;  (b)  the 
tumorigenicity of suspended cancer cells was increased by injection of the cells into polyurethane 
sponge implants;  (c) cancer cells were more tumorigenic embedded in syngeneic stroma than 
in transgenic antigenic stroma expressing the K 2t6 major histocompatibility complex class  I 
antigen; and (d) antigenic, bone marrow-derived, stromal components (presumably passenger 
leukocytes) were suflident to cause rejection of immunogenic but antigenically unrelated cancer. 
Together, these studies show that the stromal milieu helps determine the outcome of the complex 
interaction between host immunity and cancer cells and suggests a new mode of immunotherapy 
based  upon  targeting  of antigenic leukocytes to  the  tumor  site  to  serve as  stimulators  of 
immunological rejection of cancer. 
M 
alignant cells of solid cancers invade surrounding normal 
tissues; thus, cancer cells 1 become embedded in a ma- 
trix of nonmalignant tissue consisting of vessels, sessile and 
migratory cells, and extracellular matrix, which together are 
termed "tumor stroma" (1). Tumor stroma seems to play a 
complex role in tumor growth. Cancers can invade and de- 
stroy the surrounding normal tissues, including stroma; how- 
ever, tumor stroma is essential for providing blood supply 
and other factors that affect the growth of cancers.  While 
some tumors use mainly preexisting surrounding tissues as 
stroma, other cancers induce formation of new stroma. Some 
cancers influence surrounding stroma by inducing expression 
of surface antigens on stromal cells (2). The interactions be- 
tween cancer cells and stroma are poorly understood, but prob- 
ably affect invasion and metastasis by malignant cells (for re- 
view see references 3 and 4) as well as infiltration and reactivity 
1 Carcinomas and sarcomas are referred to as malignancies or cancers, and 
cells derived from them as cancer cells or tumor cells, while the term tumor 
or tumorigenic describes the mass or growth produced by the cancer cells. 
of immune and other cells of inflammation. The study of 
such stromal interactions may, therefore, reveal new targets 
for alternative therapeutic strategies against solid tumors. In 
the previous study, we show that while nonantigenic stroma 
may prevent effective immunological destruction of malig- 
nant cells, antigenic stroma can lead to rejection of cancer 
cells that are embedded in it. 
Materials and Methods 
Mice.  5-wk-old female C3H/HeN  (mammary tumor virus- 
negative  [MTV-]  2)  mice  from  colonies  of germfree-derived, 
defined  flora animals were purchased  from the NCI Frederick  Cancer 
Research Facility (Frederick, MD). The original stock of nude C3H 
mice was in its 23rd backcross generation when obtained from a 
colony of the Biology Division of the Oak Ridge National Labora- 
tory (Oak Ridge, TN). After 1988, the nude mice of this strain 
were purchased from the NCI Frederick Cancer Research Facility. 
2  Abbreviations used in this paper." MTV,  mammary tumor virus;  PRO, 
progressor; TBA,  tumor-bearing animals. 
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has been described (5). Gene K 216 was isolated from a genomic li- 
brary of the 1591 RE (6) and is not identical but very similar to 
(three amino acid differences)  a K' recently duned and sequenced 
(K. Hasenkrug and S. Nathenson, personal communication). The 
transgenic mice express the K z~6 MHC class I aUoantigen with the 
same or similar tissue distribution as normal MHC class I antigens 
(5).  Before use in experiments, transgenic mice were screened  for 
expression of the K 216 gene in PBL by flow cytofluorometry. All 
mice were kept in laminar air flow hoods and were fed sterilized 
food (Purina 5010 C; Purina, Inc., St. Louis, MO) and sterilized, 
acidified  water. 
Tumor Lines.  The undifferentiated spindle cell cancer 1591-PKO 
(also designated 1591-PKO4L or 1591-VAK8 [7]) used in this study 
is one of the progressor variants observed in 5 of 100 animals that 
were challenged with fragments of the 1591 regressor tumor (8, 
9). The 1591 regressor expresses  in addition to K k and D k three 
other MHC class I genes: D q, Lq, and K 2t6, which is similar to 
K s, (6, 10, and K. Hasenkrug and S. Nathanson, personal com- 
munication).  The 1591-PRO tumor expresses  K k and D ~ MHC 
class I antigens but has lost all three MHC class I genes that are 
not of H-2  k haplotype (7, 11). Fragments of the 1591 PRO tumor 
will grow progressively in '~80% of normal mice. This progressor 
variant when transfected with the K 2~6 gene (TK3.3, designated 
K 216 tumor or 1591-RE)  is always rejected by normal C3H/HeN 
mice unless a rare variant arises with loss of the K z16 gene (7). The 
1591-MET is a highly malignant variant of the 1591 tumor that 
expresses K k and D k antigens but lacks all four previously de- 
scribed CTbdefined target antigens (11). 6132A-PRO (done 2.2), 
6118A-PRO,  (Subline PRO1), and 6134A-PRO are progressor vari- 
ants  of  recently  derived  UV-induced  regressor  tumors  from 
C3H/HeN hosts (12, 13). Morison et al. (14) have reported that 
most skin tumors induced with UV in C3H mice are of epithelial 
origin. AG-104A is a spontaneous undifferentiated malignant tumor 
that developed in the subcutaneous tissue of an aged C3H/HeN 
mouse (13). The fibrosarcoma 3152-PKO was induced in a UV- 
irradiated  C3H/HeN  mouse  by  the  subcutaneous  injection  of 
3-methylcholanthrene in non-UV-exposed skin (15). All cancer cell 
lines were cultured in vitro in MEM containing 10% heat-inactivated 
FCS (CMEM). 
Determination of Cells in Solid Tumor Fragments.  The number 
of cells injected with tumor fragments in a full trocar was esti- 
mated by comparing the volume of tumor fragments within a trocar 
and the volume of a tumor cell. The volume of tumor fragments 
within a trocar was measured by determining the volume of medium 
disphced by the fragments loaded in a 13-gange trocar (Becton Dick- 
inson & Co., Mountain View, CA). The trocar load was expelled 
onto 3MM blotting paper (3mmChr; Whatman International Ltd., 
Maidstone, England) to remove the surrounding liquid,  and the 
fragments were then immediately transferred with a forceps into 
an inverted tuberculin syringe used as volumetric vessel. The volume 
of fragments in one trocar load measured in six experiments (meas- 
uring five trocar loads for each line and four different cell lines) 
ranged from 27  +_  15 #1 SD to 31  _+  16 #1 SD (average,  29  ,+ 
14 #1 SD). The average volume of a tumor cell was determined 
by adding a large number of tissue culture cells (1-2  x  10  s) to 
1.5 ml of medium in a 2-ml pipette. The mean volume per tumor 
cell ranged from 1.95  x  10 -6  _+  0.16  x  10 -6/~1 SD to 2.15  x 
10 -6  .+  0.18  x  10 -6 /~1 SD for the four cell  lines  tested.  This 
value lies within the average range of single cell volumes (5.2  x 
10 -7 to 1.4  x  10 -s/~1) reported previously for animal cells (16). 
Using the experimental value for cultured single cancer cell volume 
of UV-induced cancer cell lines and the experimental value for the 
volume of tumor fragments injected with a trocar, the mean value 
of cancer cell number per trocar is 1.4  x  107  ,+ 0.7  x  107 tumor 
cells, which for convenience is referred to in the tables  as 1.5  x 
107 tumor cells per trocar. 
Tumor Transplantation,  Biopsy, and Reaclaptation to Culture and En- 
zymatic Digestion.  Solid tumors were obtained from nude C3H 
mice that had been inoculated with cultured cells; "ol-mm  3 frag- 
ments were transplanted subcutaneously with a trocar into anesthe- 
tized mice, either as full, 1/3, or 1/10 full trocar load. To confirm 
the 1591 lineage or K 216 antigen expression  of a tumor, fine needle 
biopsies were routinely obtained after 4-5 wk of tumor growth 
as described (5).  Tumor biopsies were expelled into CMEM con- 
taining antibiotics (penicillin,  streptomycin, and gentamycin) and 
cultured for 1 wk before flow cytofinorometric analysis of antigen 
expression. For some experiments, tumor fragments were digested 
enzymatically to generate single cell suspensions.  Fragments were 
digested in RPMI containing 10 mg deoxyribonudease,  100 mg 
collagenase (Sigma Chemical Co.,  St.  Louis,  MO),  and 250 U 
hyaluronidase (Sigma Chemical Co.) for 1 h at room temperature. 
Digested cells were filtered through a nylon screen (60-#m mesh 
width) and the suspension was then washed four times with CMEM 
and counted before use in experiment. 
Skin Transplantation.  Ventral donor skin was applied to the dorsal 
thoracic wall of the recipient using the method of Billingham and 
Medawar (17). Bandages were removed on day 7, and grafts were 
scored daily until rejection (defined as loss of at least 80% of grafted 
tissue) or the end of the experiment. 
Polyurethane Sponge Matrix Implants.  A  0.50-0.75-cm  3 poly- 
urethane  sponge  (Future  Foam  Co.,  Chicago,  IL)  was  passed 
through a skin incision anterior to the base of the tail and depos- 
ited subcutaneously in the interscapular  region of anesthetized mice. 
Sterility is crucial since the sponge graft acts as a foreign body and 
will support bacterial growth. 
Flow CytometryAnalysis.  The mAbs CP28 (18) and CP154 are 
specific for the K 216 MHC class I antigen and for a 1591 lineage- 
specific antigen, respectively.  The other anti-MHC class I mAbs 
were gifts from Dr. Keiko Ozato and their specificities have been 
described (19). 0.5-1  x  106 cells were incubated with the specific 
antibodies for 30 min on ice and then washed twice with PBS con- 
taining 10% BSA and 0.1%  sodium azide.  Next, the cells were 
incubated with fluorescein-coupled  goat anti-mouse immunoglob- 
ulin (Hyclone E-1081-A; Hyclone Laboratories, Logan, UT) for 30 
min before analyzing them on either FACS IV (Becton Dickinson 
& Co.) or on EPLCS-753 (Coulter Electronics, Hialeah, FL). The 
binding ratio was determined as the amount of fluorescence  after 
staining with both antibodies divided by the amount of fluores- 
cence after staining with the second antibody alone. 
Results 
Cancer Cells Are More Tumorigenic When Contained within 
a Stroraal Matrix.  Our studies were predicated on the initial 
observations that certain cancer call lines capable of progres- 
sive  growth  when  administered  as  solid  tissue  fragments 
("progressor [PRO] tumors") were incapable of such growth 
when administered as suspensions of calls. For example, the 
UVqnduced tumor lines 1591-PRO, 6134A-PRO, and 6132A- 
PRO each grew progressively in >50% of normal syngeneic 
C3H/HeN  mice when transplanted subcutaneously as solid 
tumor fragments (Table 1). Based on tumor size, the smallest 
fragments used contained ,,~1.5  x  106 cancer cells (see cal- 
culations in Materials and Methods). In contrast, much larger 
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Mice as Cell Suspensions or Fragments of Solid Tumors 
Tumor 
Tumor  Inocu|um*  Tumor cells  outgrowth~ 
￿  ~ 
1591-PRO  Suspension  50  O/7S 
Suspension  10  1/8 
Fragments  15  11/15 
Fragments  3  10/12 
Fragments  1.5  8/12 s 
6134A-PRO  Suspension  50  0/5 II 
Suspension  10  0/16 
Fragments  15  9/11 
Fragments  3  8/12 
Fragments  1.5  7/12 II 
6132A-PRO  Suspension  50  4/5 
Suspension  10  0/7  ~ 
Fragments  15  6/8 
Fragments  3  9/10 
Fragments  1.5  7/101 
* 8-10-wk-old  mice were used for tumor challenge. When mice were 
challenged, the last inoculum was given to a nude mouse to assure the 
viability of the fragments at the end of the experiment. For each tumor 
line, 10~ to 107 cells in suspension produced outgrowth of tumors in five 
of five nude mice. 
* Number of mice that developed tumors per number of mice challenged. 
Results involving more than five mice challenged were pooled from two 
or more experiments, each comparing the outgrowth of a tumor cell sus- 
pension with that of solid tumor fragments. Tumor incidence is listed 
at day 60 after challenge. Mice tumor free after that date were consi- 
dered cured and the experiment was terminated. 
S The difference between the two ratios with this footnote symbol was 
found to be significant by the Fisber's exact test (p <  0.015). 
U  This difference between the two ratios with this footnote symbol was 
found to be significant by the Fisher's exact test (p <  0.05). 
￿82  This difference between the two ratios with this footnote symbol was 
found to be significant by the Fisher's exact test (p <  0.01). 
doses of these same ceils were completely nontumorigenic 
when administered as suspensions of cells that had been grown 
in  tissue  culture.  Thus,  challenges  of  107  suspended  cells 
and,  for two  of the  tumors,  even 5  x  107 cells  (>33-fold 
more cells than present in the smallest fragments) were re- 
jected by virtually all recipients.  These same doses of sus- 
pended cells were fully capable of forming tumors in nude 
mice (data not  shown),  ruling  out  the possibility that  the 
particular culture conditions used had rendered the cell sus- 
pensions  nonviable  or  otherwise  incapable  of progressive 
growth  in vivo. 
To  investigate  the  reason  for  this  striking  difference  in 
tumorigenicity between  tumor fragments  and cell  suspen- 
Table  2.  Some Lines of Cancer Cells in Suspension Are More 
Tumorigenic after Injection into Subcutaneous Sponges 
Tumor outgrowth* 
Tumor cells 
Tumor  in  suspension  Sponges  Subcutaneous* 
x  10  ~ 
1591-PRO  50  5/5s  (0/7)s 
10  9/10  (1/8) 
6134A-PRO  50  1/5 II  (0/5) II 
10  0/6  (0/16) 
6132A-PRO  50  5/5  (4/5) 
10  4/61  (0/7)I 
* Number of mice that developed tumors per number of mice challenged. 
Results involving more than five mice were pooled from two or more 
experiments, see Table 1. Tumor incidence at day 60 after challenge. Mice 
tumor free after this time were considered cured and the experiment was 
terminated. 
* For comparison, tumor outgrowth of same size inocula injected sub- 
cutaneously is shown in parentheses from data presented in Table 1. 
Sponges were injected in experiments done concurrently with those in 
Table 1. 
$ The difference between the two ratios with this footnote symbol was 
found to be significant by the Fisher's exact test (p <  0.002). 
II The difference between the two ratios with this footnote symbol was 
found not to be significant by the Fisher's exact test (p  =  1.00). 
￿82  The difference between the two ratios with this footnote symbol was 
found to be significant by the Fisher's exact test (p <  0.02). 
sions, we injected the suspended cells into subcutaneous poly- 
urethane sponge implants. Indeed, the presence of the sponges 
increased the tumorigenic potential of the ceils dramatically 
(Table 2);  the tumor incidence of the  1591-PRO  tumor in- 
creased from  13 to 90%  and from 0  to  100%  for the  two 
doses of cells used. Tumor incidence for 6132A-PRO increased 
from 0 to 67% for the smallest dose of cells while the larger 
dose produced growing tumors in the absence of the sponges. 
Little growth occurred for the 6134A-PRO  tumor cells in 
the presence of the sponges, indicating a high degree of im- 
munogenicity  that  was not  overcome. 
Enzymatically digested fragments yielded suspended ceils 
that were rejected by normal mice as effectively as suspended 
cells obtained from cultures.  This was indicated in two ex- 
periments  showing  that all of 10  mice rejected either  5  x 
107 or 107 cancer cells derived from fragments of 1591-PRO, 
though these numbers of cells produced growing tumors in 
five of five nude mice. Thus,  stroma appears to be essential 
for the enhanced growth potential of solid tumor fragments. 
Stroma Is also Critical for Determining the Tumorigenicity of 
Cancer Cells in Tumor-bearing Hosts.  Normal tumor-free mice 
reject  regressor  tumor  fragments  at  any testable dose,  but 
tumor-bearing animals (TBA) fail to reject regressor tumor 
fragments (20).  TBA fail to reject even small numbers (1.5 
x  106) of K 216 regressor  tumor  cells embedded  in  stroma 
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Challenge 
Exp.  Host*  Type  Cell dose  Stroma 
Take of 
inoculum/ 
graft (%)+ 
1  Tumor-beating 
Tumor-beating 
2  Tumor-beating 
Tumor-free 
K 2~6+ tumor suspension 
K 216+ tumor suspension 
K  2t6+  tumor suspension 
K 216§  tumor fragments 
K 216+ tumor fragments 
K 216+ tumor fragments 
1591-PRO  tumor suspension 
1591-PRO  tumor suspension 
1591-PRO  tumor fragments 
K 2t6§ tumor fragments 
K 216+ tumor fragments 
K 216+ skin 
K 216+ tumor fragments 
K 216+ skin 
￿  10  + 
50  None  2/16  (13) 
10  None  0/8  (0) 
10  Sponge  5/6  (83) 
15  C3H/HeN  8/9  (88) 
5  C3H/HeN  5/5  (100) 
1.5  C3H/HeN  5/5  (100) 
50  None  9/9  (100) 
10  None  8/8  (100) 
1.5  C3H/HeN  8/8  (100) 
15  K 216+ transgenic  0/20  (0) 
15  C3H/HeN  16/16  (100) 
-  K 216+ transgenic  0/6S  (0) 
15  C3H/HeN  0/18  (0) 
-  K 2t6§  transgenic  0/6s  (0) 
* C3H/HeN mice were injected with fragments of the KZt6-negative  progressor tumor 1591-PRO (KkD  k) at one subcutaneous site (right flank). 
4-5 wk later, when tumors had reached an average volume of 2-5 cm  3, these tumor-bearing mice were challenged with the type of tissue indicated 
(left flanks). 
* Tumor-free or tumor-beating  C3H/HeN mice (KkD  k) received K  216+ transgenic full thickness skin grafts (KkDkK  z16) or were injected with one 
trocar load of the K  216+ transfected tumor (KkDkK  2t6) that had been grown up C3H/HeN or K  z16 transgenic mice, or were injected with a suspen- 
sion of K216-transfected tumor cells. Exps. 1 and 2 were pooled from two or more individual experiments. The last tumor inoculum was given 
to a nude mouse to assure viability of the fragments until the end of the challenge experiment. Mice that were tumor free at day 60 after challenge 
were considered cured and the experiment was terminated. 
S Survival of the transplanted K  zj6 transgenic skin was 15 (_+  1) and 13 (_+  1) d (+  SD) in tumor-beating  and tumor-free mice, respectively. 
but usually do reject as many as 5  x  107 suspended regressor 
tumor cells (Table 3, Exp.  1). However, just 107 suspended 
regressor tumor cells grew out when injected into sponges 
in the TBA. The lesser immune resistance of the TBA is also 
demonstrated by inability to reject suspensions of 1591-PRO 
cells  (compare Table 1 with Table 3, Exp.  1).  The results 
showing higher tumorigenicity of 1591-RE tumor fragments 
or  1591-RE  tumor calls in sponges  for TBA (Table 3) are 
analogous to the findings using 1591-PRO in tumor-free mice 
(Tables 1 and 2), except that the higher level of immunoge- 
nicity of 1591-RE (K  z16 positivity)  can compensate  for the 
reduced immune responsiveness  of the TBA. 
Fragments Consisting of Cancer Cells in Antigenic Stroma Are 
Less Tumorigenic.  TBA reject skin grafts but not malignant 
tumor grafts even when both the skin and the tumor cells 
express the  same rejection antigen  (5).  The reason for this 
difference might be that the rejection antigen in skin is ex- 
pressed by all cells, whereas the antigen in tumor fragments 
is expressed only by cancer cells.  If this was the reason for 
the difference in the response of the mice to normal grafts 
and tumor grafts, then a tumor should be rejected more effec- 
tively if the stroma of the tumor also carried the rejection 
antigen. Indeed, Table  3, Exp. 2 shows that K216-transfected 
tumors  that had grown in K 216 transgenic mice (K216-posi- 
tive stroma) were rejected by tumor-bearing  mice whereas 
the same tumor obtained from C3H/HeN  nude mice (K  216- 
negative stroma) was not rejected. Nude mice were used be- 
cause the K216-transfected tumor does not grow in normal 
mice. In additional experiments,  several types of progressor 
tumor  cells  were  transplanted  into  normal  C3H/HeN  or 
K 216  transgenic  C3H/HeN  recipients.  The  tumors  grew 
similarly, as would be expected since the transgenic mice are 
genetically identical to C3H/HeN  mice except for the addi- 
tional  expression  of the K 2t6 gene.  Solid  tumor fragments 
obtained from these different  hosts were then  transplanted 
subcutaneously into normal mice. Transplanted tumors that 
had grown in the K 2t6 transgenic donors and therefore had 
antigenic  m 2t6  stroma  grew  with  decreased  incidence  in 
normal mice (Table 4) compared with K 216 transgenic mice. 
These results indicate that the antigenic stroma can lead to 
the  rejection  of cancer cells embedded  in  it. 
Bone Marrou~erived Antigenic Stroma Decreases the Tumorige- 
nicity of Tumor Fragments.  The stroma of a graft consists of 
sessile as well as bone marrow-derived components such as 
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Fragments* 
1.5  x  107 
Host  tumor cells  Stroma  Tumor outgrowth  (%)* 
C3H/HeN  1591-PRO  C3H/HeN  22/31  (71) s 
K 2t6§ transgenic  6/38  (16)s 
6134A-PRO  C3H/HeN  9/11  (82)11 
K 216+ transgenic  1/12  (8)11 
6132A-PRO  C3H/HeN  6/8  (75) I 
K 216+ transgenic  3/14  (21) I 
K 2t6 transgenic  1591-PRO  K 216+ transgenic  14/18  (78) 
C3H/HeN  12/18  (67) 
6134A-PRO  K 216+ transgenic  10/12  (83) 
6132A-PRO  K 216+ transgenic  12/12  (100) 
* Tumor-free C3H/HeN (KkD  k) or K ~'t6 transgenic C3H/HeN (KkDkK  2t6) mice were injected with one trocar load of solid tumor fragments of 
the progressor tumor that had grown for 5 wk or more in C3H/HeN or K 2t6 transgenic line as indicated. 
* Data pooled from two or more experiments. The last tumor inoculum was given to a nude to assure viability of the fragments until the end of 
the challenge experiment.  Mice that were tumor free for 60 d after challenge were considered cured and the experiment was then terminated. 
$ The difference between  the two ratios with this footnote  symbol was found to be significant by the Fisher's exact test (2 <  0.0001). 
II The difference between the two ratios with this footnote  symbol was found to be significant by the Fisher's exact test (p <  0.0002). 
I The difference between  the two ratios with this footnote  symbol was found to be significant by the Fisher's exact test (p <  0.05). 
passenger leukocytes (i.e., leukocytes present in the graft at 
the  time tissue is taken for transplantation).  To determine 
whether these bone marrow-derived components contributed 
to rejection of tumor grafts, we constructed chimeras in which 
only the bone marrow-derived cells or the sessile stromal cells 
expressed  the K 216 antigen.  Thus,  we reconstituted  irradi- 
ated K 216 transgenic mice with C3H/HeN  bone marrow or 
Source of PBL 
Bone rnarrow---~- Irradiated host 
C3H/HeN  -I~-C3H/HeN  ! 
C~H/HeN  -I~- K=16  transgenic 
K z+e  transgenic -~-C.,3H/HeN  I m 
K  zla transgenic ~  K =is transgenic 
2  4  6 
K=leAntigen Expression 
(Binding Ratio) 
Figure 1.  Level  of K 216 antigen expression in peripheral white blood 
cells of bone marrow chimeras. Bars for each type of chimera represent 
the  level of K at6  antigen  expression above background  fluorescence. 
Results shown here are representative of results obtained in three indepen- 
dent experiments. For details of the generation of chimeras and cytofluoro- 
metric analysis, see Materials and Methods. 
reconstituted C3H/HeN  mice with K z16 bone marrow from 
K 2t6 transgenic mice. 1591-PILO tumors were grown in each 
type of chimera to provide a  source  of tumors  containing 
the different stromal components. Fig. 1 shows that nucleated 
PBL from chimeric C3H/HeN TBA having been reconstituted 
with  K 2t6  transgenic  bone  marrow  showed  significant 
staining  with  anti-K  2t6  antibody;  in  contrast,  PBL  of the 
K 2t6  transgenic  C3H/HeN  chimera  reconstituted  with 
C3H/HeN  bone marrow showed no K2t6-positive staining 
above the background (i.e., the level of fluorescence was equal 
to PBL from the  K2t6-negative control  C3H/HeN  TBA). 
1591-PRO  tumors  that had grown in these chimeric hosts 
were then transplanted  into recipients as indicated in Table 
5. Transplants of tumors that had grown in syngeneic mice 
reconstituted  with  K 2t6  transgenic  bone  marrow  were  re- 
jected at least as effectively as transplants of tumors that had 
grown  in  K 216  transgenic  mice;  i.e.,  the  K 216  bone 
marrow-derived stromal components were very powerful in 
decreasing the tumorigenicity of tumor fragments. We cannot 
assert that K 216 sessile elements alone can lead to rejection 
since  the  irradiated  K 216 transgenic  mice with  C3H/HeN 
bone  marrow  may have had  in  the  graft  a  few remaining 
K 216 bone marrow-derived cells that could not be detected. 
Antigenic  Tumor Stroma Does Not Decrease the Tumorigenicity 
of Poorly Immunogenic  Cancer Cells.  If rejection was caused 
solely by reaction to stroma, then highly malignant cells in 
immunogenic stroma should also be rejected. To test this pos- 
sibility several other progressor tumor cell lines,  a  sponta- 
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Tumorigenicity of Tumor Fragments 
Stroma of tumor  Tumor outgrowth 
Exp.  fragments*  (%)* 
1  C3H/HeN  8/10  (80) 
K 216 transgenic  4/13  (31) 
Chimeric:  K 216 transgenic  2/5  (40) 
reconstituted  with 
C3H/HeN  bone marrow 
2  C3H/HeN  11/15  (73)s 
K ~16 transgenic  3/15  20) 
Chimeric:  C3H/HeN 
reconstituted  with  K 216 
transgenic bone marrow  0/10  (0)s 
3  C3H/HeN  9/12  (75)11 
Chimeric:  K 216 transgenic 
reconstituted  with  C3H/ 
HeN bone marrow  3/12  (25) 
Chimeric:  C3H/HeN 
reconstituted  with  K 216 
transgenic bone  marrow  1/12  (8)It 
4  C3H/HeN  3/5  (60) 
Chimeric:  C3H/HeN 
reconstituted  with  C3H/ 
HeN bone marrow  4/5  (80) 
* Mice bearing  1591-PRO  tumors  for at least 4 wk were used; mice 
received 900 rad of whole body gamma radiation from a 13YCs source. 
Within  1 h after irradiation,  tumor bearers received 1-2  x  107 bone 
marrow cells obtained from the designated source. The irradiated recon- 
stituted  tumor bearers were used 6-7 d later as source of solid tumor 
fragments for tumor challenge. Exp. 4 served as a control showing that 
irradiation of the tumor donor did not affect  the outgrowth of that tumor 
when transplanted. 
* Tumor-free C3H/HeN mice were challenged with one trocar load of 
fragment of 1591-PRO tumors that had grown in regular C3H, chimer- 
ic C3H reconstituted with K  z16 transgenic bone marrow, K  z16 transgenic 
mice, or chimeric K  216 transgenic mice reconstituted with C3H/HeN 
bone marrow. Results pooled from two or more experiments. Mice that 
were tumor free at day 60 after challenge were considered cured and the 
experiment was terminated. 
S The difference between the two ratios with this footnote symbol was 
found to be significant by the Fisher's exact test (p <  0.0002). 
II The difference between the two ratios with this footnote symbol was 
found to be significant by the Fisher's exact test (p <  0.004). 
usually grow in normal mice. These cancer cells, when grown 
as  solid  tumors  in  normal  C3H/HeN  or  K 216  transgenic 
mice and then transplanted into normal tumor-free mice, grew 
progressively (Table 6).  Thus,  an immune  response  to  the 
stroma alone was not sufficient for rejection of poorly anti- 
genic  cancer  cells. 
Discussion 
Stroma can be critical  for preventing  or permitting  im- 
munologic destruction of cancer cells in a tumor transplant. 
Our findings,  summarized  in Fig.  2,  show  that  suspended 
cells dispersed  in  medium  and  injected  subcutaneously  are 
separated from one another, and antigens on the tumor cells 
may be exposed directly to the host's immune system, which 
leads to effective immunity. In contrast, cancer cells injected 
into sponges or injected as tumor fragments are confined to- 
gether and may fail to induce effective immunity or be pro- 
tected from destruction by host immunity; however, this pro- 
tection can be overridden by the presence of antigen on tumor 
stroma, as indicated by the rejection of cancer cells embedded 
in  transgenic  stroma. 
We do not know how nonantigenic syngeneic stroma con- 
tributes to ineffective immunological rejection of solid tumor 
fragments; one possibility is that stroma lacking antigenicity 
or  antigen-presenting  function  may  impede  migration  of 
tumor-infiltrating lymphocytes, as suggested by in vitro ex- 
periments using an artificial collagen matrix (21),  or other- 
wise prevent effective sensitization  of immune cells or im- 
mune  destruction  of  cancer  cells  after  sensitization  has 
occurred. This notion is consistent with the fact that tumor 
cells injected  into a nonantigenic  polyurethane  sponge ma- 
trix grew out. It is interesting in this regard that allogeneic 
keratinocytes grafted onto a stroma lacking antigen-presenting 
cells are not rejected by the host (22). Alternatively, contain- 
ment  of tumor  cells  in close proximity  to  one  another  by 
the syngeneic stroma may result in crossfeeding by local ac- 
cumulation of growth-promoting substances produced by the 
neous  cancer,  a  highly  malignant  UV-induced  tumor,  and 
an MCA-induced  fibrosarcoma (for which  it has been very 
difficult  or impossible  to  achieve effective immune  protec- 
tion by preimmunization),  were prepared in immunogenic 
stroma. Table 6  shows that as few as 104 AG-104A or 1591- 
MET or 106 MC-3152-PRO  tumor cells in suspension will 
Figure 2.  The outcome of inoculated immunogenic cancer cells as a 
function of stroma. 
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Challenge  * 
No. of  Outgrowth of 
Tumor cell line  Stroma  Type of inoculum  tumor cells  tumors* 
AG-104 
1591-MET 
MC-3152-PR.O 
Suspension  10  7  10/10 
104  8/10 
C3H/HeN  Fragments  (1 trocar)  1.5  x  10  7  13/13 
(0.1 trocar)  1.5  x  104  5/5 
K  216 transgenic  Fragments  (1 trocar)  1.5  x  107  13/13 
(0.1 trocar)  1.5  x  10  6  5/5 
Suspension  10  7  10/10 
104  7/10 
C3H/HeN  Fragments  (1 trocar)  1.5  x  10  7  10/10 
(0.1 trocar)  1.5  x  104  5/5 
K  216 transgenic  Fragments  (1 trocar)  1.5  x  107  10/10 
(0.1 trocar)  1.5  x  104  5/5 
Suspension  10  7  9/10 
106  4/5 
10  s  1/5 
104  0/5 
C3H/HeN  Fragments  (1 trocar)  1.5  x  10  7  12/12 
(0.1 trocar)  1.5  x  104  3/5 
K  216 transgenic  Fragments  (1 trocar)  1.5  x  107  12/12 
(0.1 trocar)  1.5  x  104  4/5 
* Normal tumor-free  C3H/HeN mice were challenged  subcutaneously  with the inoculum  indicated  as positive controls, mice were challenged  with 
1591-PKO fragments in C3H/HeN (4/5) or antigenic K  216 stroma (0/5) or challenged  with 107 tumor cells (0/5). 
* Mice that survived tumor free for 60 d after challenge were considered cured and the experiment was terminated. 
tumor cells, a possibility also consistent with the results using 
sponges. Finally, the interaction between tumor and syngeneic 
stroma of  injected tumor fragments may stimulate angiogenesis 
or enhance expression of certain integrins or other adhesion 
molecules that promote earlier or faster tumor growth, and 
thereby prevent rejection. The poor accessibility of drugs and 
host defenses to the cancer cells in solid tumors due to stroma 
could be in some part responsible for the relatively ineffec- 
tive therapy for solid tumors compared with therapy for hema- 
topoietic malignancies because the cancer cells of solid tumors 
have a very different relationship to the blood supply (23). 
We are also uncertain why antigenic stroma promotes im- 
munological rejection of a tumor. In so far as we can tell, 
the architecture of the syngeneic and transgenic stroma ap- 
pears identical, at least initially. Differences in the antige- 
nicity of the stroma appear to be the reason for our previous 
observation (5) that tumor-bearing mice fail to reject regressor 
tumors even though these mice can still reject effectively a 
simultaneous normal graft expressing the same rejection an- 
tigen. Our observations that weakly antigenic tumor cells 
can be rejected when the stroma is antigenic are potentially 
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very important because they indicate that if stromal compo- 
nents of a growing tumor can be rendered antigenic, then 
the tumor may be rejected as effectively  as an allogeneic skin 
graft. Although antigenic stroma is a laboratory artifact in 
the present studies,  some tumors may induce autogenous 
stromal antigens (2), so possibly,  such antigens could be in- 
duced in the stroma in other tumors by therapy. Our finding 
that bone marrow-derived components of antigenic stroma, 
presumably comparable with passenger leukocytes in allografts, 
are alone sufficient to cause tumor rejection of immunogenic 
tumors suggests the possibility of targeting such immune 
therapy to circulating leukocytes that specifically localize to 
the tmnor. Such leukocytes obtained from tumor-specific cyto- 
lytic T cell clones and made highly antigenic to the host by 
transfection with a gene encoding an allogeneic MHC class 
I antigen, for example,  may localize in the tumor and act 
as inducer and target of a second newly induced potent an- 
tiallogeneic immune response. Thus, understanding the basis 
for the enhanced rejection of cancer cells within an antigenic 
matrix may help us to develop new strategies for promoting 
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